{"id":"https://openalex.org/W2048424737","doi":"https://doi.org/10.1097/00001813-199909000-00005","title":"Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein","display_name":"Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein","alternate_titles":[],"publication_year":1999,"publication_date":"1999-09-01","ids":{"openalex":"https://openalex.org/W2048424737","doi":"https://doi.org/10.1097/00001813-199909000-00005","mag":"2048424737","pmid":"https://pubmed.ncbi.nlm.nih.gov/10573204"},"language":"en","primary_location":{"id":"doi:10.1097/00001813-199909000-00005","doi":"https://doi.org/10.1097/00001813-199909000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-199909000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2048424737"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5065279964","display_name":"Alex Sparreboom","orcid":"https://orcid.org/0000-0003-2660-6644","observed_orcids":["https://orcid.org/0000-0003-2660-6644"]},"institutions":[{"id":"https://openalex.org/I4405267285","display_name":"Daniel den Hoed Kliniek","ror":"https://ror.org/020rz5h24","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2801952686","https://openalex.org/I4210149908","https://openalex.org/I4405267285"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alex Sparreboom","raw_affiliation_strings":["Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, The Netherlands. sparreboom@onch.azr.nl","Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital Rotterdam, The Netherlands. sparreboom@onch.azr.nl","institution_ids":["https://openalex.org/I4405267285"]},{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967147","display_name":"Andr\u00e9 S.Th. Planting","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andr\u00e9 ST Planting","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023508449","display_name":"Roxanne C. Jewell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Roxanne C Jewell","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103479396","display_name":"Maria EL van der Burg","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Maria EL van der Burg","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110886285","display_name":"Ate van der Gaast","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ate van der Gaast","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047240860","display_name":"Peter de Bruijn","orcid":"https://orcid.org/0000-0003-3372-5756","observed_orcids":["https://orcid.org/0000-0003-3372-5756"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Peter de Bruijn","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113691409","display_name":"Walter J. Loos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Walter J Loos","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108071901","display_name":"Kees Nooter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kees Nooter","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108458465","display_name":"LuWanda H Chandler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"LuWanda H Chandler","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027768129","display_name":"Elaine Marie Paul","orcid":"https://orcid.org/0000-0002-2975-2316","observed_orcids":["https://orcid.org/0000-0002-2975-2316"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Elaine M Paul","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069473904","display_name":"Paul Stephen Wissel","orcid":"https://orcid.org/0000-0002-5790-8875","observed_orcids":["https://orcid.org/0000-0002-5790-8875"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Paul S Wissel","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110112933","display_name":"Jaap Verweij","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jaap Verweij","raw_affiliation_strings":["Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Glaxo Wellcome Inc, Research Triangle Park, NC 27709, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.4547,"has_fulltext":false,"cited_by_count":102,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.88499524,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"10","issue":"8","first_page":"719","last_page":"728"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/elacridar","display_name":"elacridar","score":0.9950000047683716},{"id":"https://openalex.org/keywords/p-glycoprotein-inhibitors","display_name":"P-glycoprotein inhibitors","score":0.8410000205039978},{"id":"https://openalex.org/keywords/multidrug-resistance","display_name":"multidrug resistance","score":0.7609999775886536},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8019999861717224},{"id":"https://openalex.org/keywords/doxorubicinol","display_name":"doxorubicinol","score":0.9279999732971191},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.7850000262260437},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.800000011920929},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.7950000166893005},{"id":"https://openalex.org/keywords/platelet-count","display_name":"platelet count","score":0.5839999914169312},{"id":"https://openalex.org/keywords/cancer-chemotherapy","display_name":"cancer chemotherapy","score":0.41200000047683716}],"concepts":[{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.8745287656784058},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7863246202468872},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7034372687339783},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5226119160652161},{"id":"https://openalex.org/C2778707650","wikidata":"https://www.wikidata.org/wiki/Q412902","display_name":"P-glycoprotein","level":4,"score":0.5202904343605042},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.49230730533599854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47488826513290405},{"id":"https://openalex.org/C133936738","wikidata":"https://www.wikidata.org/wiki/Q643839","display_name":"Multiple drug resistance","level":3,"score":0.4191198945045471},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3776940107345581},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31657660007476807},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2915037274360657},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.13305869698524475},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08274537324905396}],"mesh":[{"descriptor_ui":"D000166","descriptor_name":"Acridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000652","qualifier_name":"urine","is_major_topic":false},{"descriptor_ui":"D001792","descriptor_name":"Blood Platelets","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000652","qualifier_name":"urine","is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009504","descriptor_name":"Neutrophils","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018432","descriptor_name":"Drug Resistance, Multiple","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019008","descriptor_name":"Drug Resistance, Neoplasm","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020168","descriptor_name":"ATP Binding Cassette Transporter, Subfamily B, Member 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D044005","descriptor_name":"Tetrahydroisoquinolines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":4,"locations":[{"id":"doi:10.1097/00001813-199909000-00005","doi":"https://doi.org/10.1097/00001813-199909000-00005","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-199909000-00005","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:10573204","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10573204","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Clinical Trial"},{"id":"pmh:oai:pure.eur.nl:openaire_cris_publications/4d045972-856e-48b9-80ee-cbd410bcf0d4","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/4d045972-856e-48b9-80ee-cbd410bcf0d4","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Sparreboom, A, Planting, AST, Jewell, RC, Burg, MEL, van der Gaast, A, de Bruijn, P, Loos, W, Nooter, K, Chandler, LWH, Paul, EM, Wissel, PS & Verweij, J 1999, 'Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein', Anti-Cancer Drugs, vol. 10, pp. 719-728.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:eur:oai:pure.eur.nl:publications/4d045972-856e-48b9-80ee-cbd410bcf0d4","doi":null,"is_oa":false,"landing_page_url":"https://pure.eur.nl/en/publications/4d045972-856e-48b9-80ee-cbd410bcf0d4","pdf_url":null,"source":{"id":"https://openalex.org/S4306401266","display_name":"EUR Research Repository (Erasmus University Rotterdam)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913958620","host_organization_name":"Erasmus University Rotterdam","host_organization_lineage":["https://openalex.org/I913958620"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Anti-Cancer Drugs, 10, 719 - 728. Lippincott Williams &amp; Wilkins","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W91819048","https://openalex.org/W2001361864","https://openalex.org/W2164737534","https://openalex.org/W1973464283","https://openalex.org/W2740003291","https://openalex.org/W64171703","https://openalex.org/W1988234658","https://openalex.org/W2086836710","https://openalex.org/W6957939416","https://openalex.org/W1965295365"],"abstract_inverted_index":{"Previous":[0],"clinical":[1],"investigations":[2],"with":[3,65,167,247,251,280],"doxorubicin":[4,36,66,88,105,119,248,279],"indicated":[5],"that":[6,222,234,283],"modulators":[7],"of":[8,15,22,35,54,87,118,125,133,153,172,187,214,228,266,270,278],"P-glycoprotein":[9,42,271],"dramatically":[10],"decrease":[11,192],"the":[12,16,20,28,33,85,121,134,138,182,185,190,200,225,243,264,274,281],"systemic":[13],"clearance":[14],"drug,":[17],"which":[18,164],"complicates":[19],"interpretation":[21],"toxicity":[23,275],"and":[24,37,84,89,93,102,106,189,195,240,276],"response":[25],"data.":[26],"In":[27],"present":[29],"study,":[30],"we":[31],"examined":[32],"pharmacokinetics":[34],"GF120918,":[38],"a":[39,48,69,111,128,267],"novel":[40],"potent":[41,268],"inhibitor,":[43],"in":[44,47,120,193,199,237,259],"cancer":[45],"patients":[46,154],"search":[49],"for":[50,104],"more":[51],"selective":[52],"modulation":[53],"multidrug":[55],"resistance":[56],"(MDR).":[57],"Seven":[58],"cohorts":[59],"(46":[60],"patients)":[61],"received":[62],"sequential":[63],"treatments":[64],"alone":[67,78],"by":[68,110,217],"5":[70],"min":[71],"i.v.":[72],"bolus":[73],"(50-75":[74],"mg/m2),":[75],"oral":[76],"GF120918":[77,126,223],"(50":[79],"mg":[80,82,148],"q.d.-400":[81],"b.i.d.),":[83],"combination":[86,229],"GF120918.":[90,173,218],"Serial":[91],"blood":[92],"urine":[94],"samples":[95],"were":[96,204],"taken":[97],"during":[98],"both":[99,207],"treatment":[100,208,230],"courses":[101],"analyzed":[103],"its":[107],"metabolite":[108],"doxorubicinol":[109,160,188,215],"liquid":[112],"chromatographic":[113],"assay.":[114],"The":[115],"pharmacokinetic":[116,286],"characteristics":[117],"presence":[122],"or":[123],"absence":[124],"indicate":[127,221],"very":[129],"minor":[130],"overall":[131],"effect":[132],"modulator,":[135],"except":[136],"at":[137,224],"highest":[139],"combined":[140,162],"dose":[141],"level":[142],"(i.e.":[143],"75":[144],"mg/m2":[145],"plus":[146],"400":[147],"b.i.d.).":[149],"A":[150],"limited":[151],"number":[152],"experienced":[155],"significantly":[156],"increased":[157],"exposure":[158],"to":[159,262,273],"upon":[161],"treatment,":[163],"was":[165],"associated":[166],"concomitantly":[168],"higher":[169],"plasma":[170,232,285],"levels":[171],"Sigmoidal":[174],"maximum-effect":[175],"models":[176,239],"revealed":[177],"significant":[178,244],"correlations":[179],"(p<0.02)":[180],"between":[181,206],"area":[183],"under":[184],"curve":[186],"percent":[191],"neutrophils":[194],"platelets.":[196],"Sigmoidicity":[197],"factors":[198],"fitted":[201],"Hill":[202],"equation":[203],"similar":[205],"courses,":[209],"suggesting":[210],"no":[211],"pharmacodynamic":[212],"potentiation":[213],"myelotoxicity":[216],"Our":[219],"data":[220],"tested":[226],"doses":[227],"achieves":[231],"concentrations":[233],"reverse":[235],"MDR":[236],"experimental":[238],"it":[241,255],"lacks":[242],"kinetic":[245],"interaction":[246],"observed":[249],"previously":[250],"other":[252],"modulators.":[253],"Hence,":[254],"may":[256],"be":[257],"possible":[258],"future":[260],"trials":[261],"assess":[263],"contribution":[265],"inhibitor":[269],"activity":[272,277],"knowledge":[282],"profound":[284],"interactions":[287],"are":[288],"unlikely.":[289]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2048424737","counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
